Pre-RA studies: a summary by Dr. Deane #ACR22 @RheumNow https://t.co/HU8JWmYM8H

One of the nicest, smartest, and hardest working young rheumatologists you will meet, and I'm sure is destined for great things. My hat off to you @SattuiSEMD, congratulations! #ACR22 @RheumNow https://t.co/dzHXeahsHT

• https://twitter.com/rheum_cat/status/1591849758859341824

Is channelling bias a risk, because of treating clinicians 'protecting' pre-existing autoimmune dx pts: maybe? Certainly in practice, these pts might get less combo immunoRx; this @mcgillu data would suggest so Much more to understand across tumor streams ABST0760 #ACR22 https://t.co/z1rhAJZ9gj

What imaging modality is best in GCA? Dutch study: n=42 ?GCA got all three of USS, PET/CT, MRI Overall performance basically the same between all three. Important details in 🧵 but reasonable to say you can be happy with whatever you’ve got! ABST1617 #ACR22 #ACRBest @RheumNow https://t.co/HGt0vW9Z38

To propose early intervention in pre-clinical PsA we need to first identify pts! Eder et al. PRESTO Prediction of Psoriatic Arthritis Tool Dvlped 600+ Pso M stiff, PASI, nails, fatigue pain severity Sens 61% Spe 77% for 5% proba PsA onset w/in 5yrs Abs#1612 #ACR22 @Rheumnow https://t.co/QYOIKe3nui

Tapryal et al. Diagnostic delay of >6 months contributes to poor PROs in PsA. @RheumNow #ACR22 Abstr#1507 https://t.co/dkaNhXUAeD https://t.co/6G7X7V1aRI

• Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Out…

Data like this make us think even in the setting of a controlled clinical trial in #gout, non-white patients much less likely to achieve target serum urate! Black pts 70% less likely to reach target compared to whites! #ACR22 @RheumNow abst#1583 https://t.co/dYet7pk2l5

Jones et al. Non-smokers, normal BMI, and current drinkers! with AxSpA more likely to respond to TNFi. @RheumNow #ACR22 Abstr#1510 https://t.co/inCz2sAyj5 https://t.co/K27ptuLV7Y

• Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of T…

Everyday heroes during #COVID19 Keynote @ACRheum Health care workers who were minorities disproportionately died in the early days of the pandemic. Can’t be all SES as risk but maybe ‘status’ as first line workers. Remember them #ACRBest #ACR22 @RheumNow @AbrahamVerghese 🙏🏻 https://t.co/AjkV5wDVEu

Only 4 minutes to discuss adherence in #SLE. Implementation of discussion if <80% of meds filled. Academic docs - 20/24 used + reinforcement, validated in 17 Pts, 11/24 asked open ended ?s. Pts thought it was right timing. ?does it change behaviour- ? Abst0063 @RheumNow #ACR22 https://t.co/UQbRgw5Emj

Sunday: ACR 2022 Daily Recap https://t.co/9naWAYwJIV

• https://twitter.com/i/broadcasts/1ZkJzXgkMqoKv

#ClinicalPearl woman with non-radiographic axSpA have LESS inactive disease vs MEN but NOT true if radiographic axSpA. 5 yr global study N=2633, independent of TNFi use - not sure why there are differences. Misclassification dx- unlikely. abst#1614 #ACR22 #ACRBest @RheumNowNews https://t.co/coNjwHOkLP

Lifetime career achievement ✔️ - first author of a paper in ACR year in review #ACR22 https://t.co/M5GrOcWY5X

• https://twitter.com/rheum_cat/status/1591452540067090434

$26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered (could only be obtained if ANA +); intervention aimed at inappropriate testing by ortho, IM, family med and neuro abst#0058 #ACR22 @rheumnow https://t.co/GoDHat6N3v

• Health System Improvement in Inpatient ANA and Serologic Test Utilization - ACR…